US equities
|
MU
$904.14
▼-0.08%
NVDA
$216.60
▼-0.23%
SPCX
$147.07
▼-0.60%
TSLA
$375.15
▲+1.93%
META
$689.11
▼-2.31%
AAPL
$339.20
▼-1.09%
SNDK
$1,372.37
▲+0.09%
INTC
$92.42
▲+0.43%
MU
$904.14
▼-0.08%
NVDA
$216.60
▼-0.23%
SPCX
$147.07
▼-0.60%
TSLA
$375.15
▲+1.93%
META
$689.11
▼-2.31%
AAPL
$339.20
▼-1.09%
SNDK
$1,372.37
▲+0.09%
INTC
$92.42
▲+0.43%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Aprea Therapeutics
< Previous
1
2
Next >
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
October 16, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present at October Conferences
October 05, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
September 22, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 10, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
August 28, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
August 12, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
July 30, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
June 01, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
May 13, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
April 21, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement
April 01, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement
March 30, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial
March 30, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
March 16, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial
February 18, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 17, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
February 12, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
February 04, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan
January 29, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules
January 29, 2026
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
December 18, 2025
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
December 09, 2025
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
November 12, 2025
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
October 24, 2025
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies
October 15, 2025
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2025
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
August 28, 2025
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update
August 12, 2025
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
June 25, 2025
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
May 14, 2025
From
Aprea Therapeutics
Via
GlobeNewswire
Tickers
APRE
< Previous
1
2
Next >
